Premium
Structure based drug design with Diabetic Retinopathy and Rage
Author(s) -
Sriramoju Swetha,
Evangelista Diana Evangelista,
Goetz Kerry Goetz
Publication year - 2017
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.31.1_supplement.673.5
Subject(s) - glycation , diabetic retinopathy , medicine , rage (emotion) , drug , receptor , retinopathy , pharmacology , diabetes mellitus , endocrinology , biology , neuroscience
Objective Diabetic Retinopathy is the leading cause of blindness, stimulating the rise in 20,000 cases in the United States per year, and leaving over 3 million individuals vulnerable at risk. During the early stages of Diabetic Retinopathy, inflammatory and innate immune responses are derivative from pattern‐recognition receptors (PRRs) expressed as Advanced Glycation End‐products (AGEs). It has been observed that AGEs increases the progression of retinopathy in patients enduring the early stages of retinopathy. The reason behind the complication progression induced by AGEs is the ligand ‐ receptor binding with the Receptor Advanced Glycation End‐products. Therefore, by instituting a drug to bind with RAGE, may prevent the ligand‐receptor binding between RAGEs and AGEs. The following study analyzed drug targets based on their hydrophobicity, as to whether they will be able to bind with RAGE. Methods A docking program, AutoDock Tools and AutoDock Vina, were both used to determine the binding affinity, rmsd values, and Log P values of the drug targets. Results It was found that Statin drugs and Fibric Acid drugs are the types of drugs that were able to bind with RAGE with a high hydrophobicity and affinity, while a very popularly marketed drug, Metformin, wasn't able to bind with RAGE. Conclusion RAGE may be of importance in the prevention and management of diabetes complications. Support or Funding Information none